FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics. A method involves decreasing an amount or activity of CCL21 in fibrocytes and/or fibroblasts found in a fibrous defect site in said fibrous defect wherein decreasing the amount or activity of CCL21 provides the contact of said mammal with an agent decreasing the amount or activity of CCL21 in said fibroblasts. Said agent is introduced in the amount effective to relief one or more symptoms of said chronic fibrous defect.
EFFECT: group of inventions enables decreasing the number of fibrous defects and effectively treating symptoms of fibrous defects.
23 cl, 16 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROUS DISEASES | 2010 |
|
RU2561672C2 |
| BLOCK OF CCL18 SIGNALING THROUGH CCR6 AS THERAPEUTIC METHOD OF TREATING FIBROTIC DISEASES AND CANCER | 2011 |
|
RU2609649C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| ALPHA-V BETA-8-BINDING ANTIBODIES | 2012 |
|
RU2614252C2 |
| METHODS FOR PREDICTING RISK OF INTERSTITIAL PNEUMONIA | 2014 |
|
RU2670148C2 |
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| DNA-VACCINE AGAINST TUMORAL GROWTH AND WAYS OF THEIR APPLICATION | 2004 |
|
RU2343195C2 |
| VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
